YD Bio Limited Ordinary Shares's net income is $-3M, below the Healthcare sector average of $16B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2025
Trailing 12 months ending Jun 2025
Loading...
Loading...
YD Bio Limited Ordinary Shares (YDES) currently reports a net income of $-3M as of June 2025. That is below the Healthcare sector average of $16B. Use the charts on this page to explore YD Bio Limited Ordinary Shares's net income history and peer comparisons.
YD Bio Limited Ordinary Shares's net income of $-3M is lower than the Healthcare sector average of $16B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
YD Bio Limited Ordinary Shares reported $-3M in net income as of June 2025. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net income of $-3M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for YD Bio Limited Ordinary Shares, and consider following YDES for alerts when major investors trade the stock.
YD Bio Limited Ordinary Shares is classified in the Healthcare sector. On net income, it currently shows $-3M versus a sector average near $16B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing YDES with unrelated industries.